LWA
ABUS icon

Ledgewood Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

Ledgewood Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Hold
278,436
– – 0.71% 24
2026
Q1 		$1.25M Hold
278,436
– – 0.71% 26
2025
Q4 		$1.34M Hold
278,436
– – 0.77% 25
2025
Q3 		$1.26M Hold
278,436
– – 0.75% 28
2025
Q2 		$860K Hold
278,436
– – 0.54% 30
2025
Q1 		$972K Hold
278,436
– – 0.63% 28
2024
Q4 		$910K Hold
278,436
– – 0.59% 29
2024
Q3 		$1.07M Hold
278,436
– – 0.72% 25
2024
Q2 		$860K Hold
278,436
– – 0.74% 25
2024
Q1 		$718K Hold
278,436
– – 0.67% 24
2023
Q4 		$696K Buy
+278,436
New +$545K 0.64% 25

Other funds holding ABUS

EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ledgewood Wealth Advisors's ABUS Position: Q2 2026 in Review

Ledgewood Wealth Advisors held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 278,436 shares worth $1.34M. The position accounts for 0.71% of the portfolio, ranked #24.

Ledgewood Wealth Advisors first reported a position in ABUS in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.34M in Q4 2025. 4 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Ledgewood Wealth Advisors held 278,436 shares of Arbutus Biopharma worth $1.34M as of Q2 2026.
  • Ledgewood Wealth Advisors left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up 0.71% of Ledgewood Wealth Advisors's portfolio in Q2 2026, its #24 holding.
  • Ledgewood Wealth Advisors first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 11 quarters since.
  • Ledgewood Wealth Advisors's Arbutus Biopharma position peaked at $1.34M in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Ledgewood Wealth Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.